Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4
Background The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden. However, this observation does not exclude the existence of neoantigen-specific T cells i...
Gespeichert in:
| Veröffentlicht in: | Genome medicine Jg. 11; H. 1; S. 87 - 15 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
London
BioMed Central
30.12.2019
BioMed Central Ltd Springer Nature B.V BMC |
| Schlagworte: | |
| ISSN: | 1756-994X, 1756-994X |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Background
The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden. However, this observation does not exclude the existence of neoantigen-specific T cells in colorectal cancers with low mutation burden and the exploitation of their anti-cancer potential for immunotherapy. Therefore, we investigated whether autologous neoantigen-specific T cell responses could also be observed in patients diagnosed with mismatch repair-proficient colorectal cancers.
Methods
Whole-exome and transcriptome sequencing were performed on cancer and normal tissues from seven colorectal cancer patients diagnosed with mismatch repair-proficient tumors to detect putative neoantigens. Corresponding neo-epitopes were synthesized and tested for recognition by
in vitro
expanded T cells that were isolated from tumor tissues (tumor-infiltrating lymphocytes) and from peripheral mononuclear blood cells stimulated with tumor material.
Results
Neoantigen-specific T cell reactivity was detected to several neo-epitopes in the tumor-infiltrating lymphocytes of three patients while their respective cancers expressed 15, 21, and 30 non-synonymous variants. Cell sorting of tumor-infiltrating lymphocytes based on the co-expression of CD39 and CD103 pinpointed the presence of neoantigen-specific T cells in the CD39
+
CD103
+
T cell subset. Strikingly, the tumors containing neoantigen-reactive TIL were classified as consensus molecular subtype 4 (CMS4), which is associated with TGF-β pathway activation and worse clinical outcome.
Conclusions
We have detected neoantigen-targeted reactivity by autologous T cells in mismatch repair-proficient colorectal cancers of the CMS4 subtype. These findings warrant the development of specific immunotherapeutic strategies that selectively boost the activity of neoantigen-specific T cells and target the TGF-β pathway to reinforce T cell reactivity in this patient group. |
|---|---|
| AbstractList | The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden. However, this observation does not exclude the existence of neoantigen-specific T cells in colorectal cancers with low mutation burden and the exploitation of their anti-cancer potential for immunotherapy. Therefore, we investigated whether autologous neoantigen-specific T cell responses could also be observed in patients diagnosed with mismatch repair-proficient colorectal cancers. Whole-exome and transcriptome sequencing were performed on cancer and normal tissues from seven colorectal cancer patients diagnosed with mismatch repair-proficient tumors to detect putative neoantigens. Corresponding neo-epitopes were synthesized and tested for recognition by in vitro expanded T cells that were isolated from tumor tissues (tumor-infiltrating lymphocytes) and from peripheral mononuclear blood cells stimulated with tumor material. Neoantigen-specific T cell reactivity was detected to several neo-epitopes in the tumor-infiltrating lymphocytes of three patients while their respective cancers expressed 15, 21, and 30 non-synonymous variants. Cell sorting of tumor-infiltrating lymphocytes based on the co-expression of CD39 and CD103 pinpointed the presence of neoantigen-specific T cells in the CD39.sup.+CD103.sup.+ T cell subset. Strikingly, the tumors containing neoantigen-reactive TIL were classified as consensus molecular subtype 4 (CMS4), which is associated with TGF-[beta] pathway activation and worse clinical outcome. We have detected neoantigen-targeted reactivity by autologous T cells in mismatch repair-proficient colorectal cancers of the CMS4 subtype. These findings warrant the development of specific immunotherapeutic strategies that selectively boost the activity of neoantigen-specific T cells and target the TGF-[beta] pathway to reinforce T cell reactivity in this patient group. The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden. However, this observation does not exclude the existence of neoantigen-specific T cells in colorectal cancers with low mutation burden and the exploitation of their anti-cancer potential for immunotherapy. Therefore, we investigated whether autologous neoantigen-specific T cell responses could also be observed in patients diagnosed with mismatch repair-proficient colorectal cancers. Whole-exome and transcriptome sequencing were performed on cancer and normal tissues from seven colorectal cancer patients diagnosed with mismatch repair-proficient tumors to detect putative neoantigens. Corresponding neo-epitopes were synthesized and tested for recognition by in vitro expanded T cells that were isolated from tumor tissues (tumor-infiltrating lymphocytes) and from peripheral mononuclear blood cells stimulated with tumor material. Neoantigen-specific T cell reactivity was detected to several neo-epitopes in the tumor-infiltrating lymphocytes of three patients while their respective cancers expressed 15, 21, and 30 non-synonymous variants. Cell sorting of tumor-infiltrating lymphocytes based on the co-expression of CD39 and CD103 pinpointed the presence of neoantigen-specific T cells in the CD39 CD103 T cell subset. Strikingly, the tumors containing neoantigen-reactive TIL were classified as consensus molecular subtype 4 (CMS4), which is associated with TGF-β pathway activation and worse clinical outcome. We have detected neoantigen-targeted reactivity by autologous T cells in mismatch repair-proficient colorectal cancers of the CMS4 subtype. These findings warrant the development of specific immunotherapeutic strategies that selectively boost the activity of neoantigen-specific T cells and target the TGF-β pathway to reinforce T cell reactivity in this patient group. Background The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden. However, this observation does not exclude the existence of neoantigen-specific T cells in colorectal cancers with low mutation burden and the exploitation of their anti-cancer potential for immunotherapy. Therefore, we investigated whether autologous neoantigen-specific T cell responses could also be observed in patients diagnosed with mismatch repair-proficient colorectal cancers. Methods Whole-exome and transcriptome sequencing were performed on cancer and normal tissues from seven colorectal cancer patients diagnosed with mismatch repair-proficient tumors to detect putative neoantigens. Corresponding neo-epitopes were synthesized and tested for recognition by in vitro expanded T cells that were isolated from tumor tissues (tumor-infiltrating lymphocytes) and from peripheral mononuclear blood cells stimulated with tumor material. Results Neoantigen-specific T cell reactivity was detected to several neo-epitopes in the tumor-infiltrating lymphocytes of three patients while their respective cancers expressed 15, 21, and 30 non-synonymous variants. Cell sorting of tumor-infiltrating lymphocytes based on the co-expression of CD39 and CD103 pinpointed the presence of neoantigen-specific T cells in the CD39.sup.+CD103.sup.+ T cell subset. Strikingly, the tumors containing neoantigen-reactive TIL were classified as consensus molecular subtype 4 (CMS4), which is associated with TGF-[beta] pathway activation and worse clinical outcome. Conclusions We have detected neoantigen-targeted reactivity by autologous T cells in mismatch repair-proficient colorectal cancers of the CMS4 subtype. These findings warrant the development of specific immunotherapeutic strategies that selectively boost the activity of neoantigen-specific T cells and target the TGF-[beta] pathway to reinforce T cell reactivity in this patient group. Keywords: Mismatch repair-proficient (MMR-p), Tumor-infiltrating lymphocytes, Transforming growth factor-beta, Cancer immunotherapy, Adoptive T cell transfer (ACT), Low mutation burden, Neoantigen, CMS Abstract Background The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden. However, this observation does not exclude the existence of neoantigen-specific T cells in colorectal cancers with low mutation burden and the exploitation of their anti-cancer potential for immunotherapy. Therefore, we investigated whether autologous neoantigen-specific T cell responses could also be observed in patients diagnosed with mismatch repair-proficient colorectal cancers. Methods Whole-exome and transcriptome sequencing were performed on cancer and normal tissues from seven colorectal cancer patients diagnosed with mismatch repair-proficient tumors to detect putative neoantigens. Corresponding neo-epitopes were synthesized and tested for recognition by in vitro expanded T cells that were isolated from tumor tissues (tumor-infiltrating lymphocytes) and from peripheral mononuclear blood cells stimulated with tumor material. Results Neoantigen-specific T cell reactivity was detected to several neo-epitopes in the tumor-infiltrating lymphocytes of three patients while their respective cancers expressed 15, 21, and 30 non-synonymous variants. Cell sorting of tumor-infiltrating lymphocytes based on the co-expression of CD39 and CD103 pinpointed the presence of neoantigen-specific T cells in the CD39+CD103+ T cell subset. Strikingly, the tumors containing neoantigen-reactive TIL were classified as consensus molecular subtype 4 (CMS4), which is associated with TGF-β pathway activation and worse clinical outcome. Conclusions We have detected neoantigen-targeted reactivity by autologous T cells in mismatch repair-proficient colorectal cancers of the CMS4 subtype. These findings warrant the development of specific immunotherapeutic strategies that selectively boost the activity of neoantigen-specific T cells and target the TGF-β pathway to reinforce T cell reactivity in this patient group. Background The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden. However, this observation does not exclude the existence of neoantigen-specific T cells in colorectal cancers with low mutation burden and the exploitation of their anti-cancer potential for immunotherapy. Therefore, we investigated whether autologous neoantigen-specific T cell responses could also be observed in patients diagnosed with mismatch repair-proficient colorectal cancers. Methods Whole-exome and transcriptome sequencing were performed on cancer and normal tissues from seven colorectal cancer patients diagnosed with mismatch repair-proficient tumors to detect putative neoantigens. Corresponding neo-epitopes were synthesized and tested for recognition by in vitro expanded T cells that were isolated from tumor tissues (tumor-infiltrating lymphocytes) and from peripheral mononuclear blood cells stimulated with tumor material. Results Neoantigen-specific T cell reactivity was detected to several neo-epitopes in the tumor-infiltrating lymphocytes of three patients while their respective cancers expressed 15, 21, and 30 non-synonymous variants. Cell sorting of tumor-infiltrating lymphocytes based on the co-expression of CD39 and CD103 pinpointed the presence of neoantigen-specific T cells in the CD39+CD103+ T cell subset. Strikingly, the tumors containing neoantigen-reactive TIL were classified as consensus molecular subtype 4 (CMS4), which is associated with TGF-β pathway activation and worse clinical outcome. Conclusions We have detected neoantigen-targeted reactivity by autologous T cells in mismatch repair-proficient colorectal cancers of the CMS4 subtype. These findings warrant the development of specific immunotherapeutic strategies that selectively boost the activity of neoantigen-specific T cells and target the TGF-β pathway to reinforce T cell reactivity in this patient group. The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden. However, this observation does not exclude the existence of neoantigen-specific T cells in colorectal cancers with low mutation burden and the exploitation of their anti-cancer potential for immunotherapy. Therefore, we investigated whether autologous neoantigen-specific T cell responses could also be observed in patients diagnosed with mismatch repair-proficient colorectal cancers.BACKGROUNDThe efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden. However, this observation does not exclude the existence of neoantigen-specific T cells in colorectal cancers with low mutation burden and the exploitation of their anti-cancer potential for immunotherapy. Therefore, we investigated whether autologous neoantigen-specific T cell responses could also be observed in patients diagnosed with mismatch repair-proficient colorectal cancers.Whole-exome and transcriptome sequencing were performed on cancer and normal tissues from seven colorectal cancer patients diagnosed with mismatch repair-proficient tumors to detect putative neoantigens. Corresponding neo-epitopes were synthesized and tested for recognition by in vitro expanded T cells that were isolated from tumor tissues (tumor-infiltrating lymphocytes) and from peripheral mononuclear blood cells stimulated with tumor material.METHODSWhole-exome and transcriptome sequencing were performed on cancer and normal tissues from seven colorectal cancer patients diagnosed with mismatch repair-proficient tumors to detect putative neoantigens. Corresponding neo-epitopes were synthesized and tested for recognition by in vitro expanded T cells that were isolated from tumor tissues (tumor-infiltrating lymphocytes) and from peripheral mononuclear blood cells stimulated with tumor material.Neoantigen-specific T cell reactivity was detected to several neo-epitopes in the tumor-infiltrating lymphocytes of three patients while their respective cancers expressed 15, 21, and 30 non-synonymous variants. Cell sorting of tumor-infiltrating lymphocytes based on the co-expression of CD39 and CD103 pinpointed the presence of neoantigen-specific T cells in the CD39+CD103+ T cell subset. Strikingly, the tumors containing neoantigen-reactive TIL were classified as consensus molecular subtype 4 (CMS4), which is associated with TGF-β pathway activation and worse clinical outcome.RESULTSNeoantigen-specific T cell reactivity was detected to several neo-epitopes in the tumor-infiltrating lymphocytes of three patients while their respective cancers expressed 15, 21, and 30 non-synonymous variants. Cell sorting of tumor-infiltrating lymphocytes based on the co-expression of CD39 and CD103 pinpointed the presence of neoantigen-specific T cells in the CD39+CD103+ T cell subset. Strikingly, the tumors containing neoantigen-reactive TIL were classified as consensus molecular subtype 4 (CMS4), which is associated with TGF-β pathway activation and worse clinical outcome.We have detected neoantigen-targeted reactivity by autologous T cells in mismatch repair-proficient colorectal cancers of the CMS4 subtype. These findings warrant the development of specific immunotherapeutic strategies that selectively boost the activity of neoantigen-specific T cells and target the TGF-β pathway to reinforce T cell reactivity in this patient group.CONCLUSIONSWe have detected neoantigen-targeted reactivity by autologous T cells in mismatch repair-proficient colorectal cancers of the CMS4 subtype. These findings warrant the development of specific immunotherapeutic strategies that selectively boost the activity of neoantigen-specific T cells and target the TGF-β pathway to reinforce T cell reactivity in this patient group. Background The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden. However, this observation does not exclude the existence of neoantigen-specific T cells in colorectal cancers with low mutation burden and the exploitation of their anti-cancer potential for immunotherapy. Therefore, we investigated whether autologous neoantigen-specific T cell responses could also be observed in patients diagnosed with mismatch repair-proficient colorectal cancers. Methods Whole-exome and transcriptome sequencing were performed on cancer and normal tissues from seven colorectal cancer patients diagnosed with mismatch repair-proficient tumors to detect putative neoantigens. Corresponding neo-epitopes were synthesized and tested for recognition by in vitro expanded T cells that were isolated from tumor tissues (tumor-infiltrating lymphocytes) and from peripheral mononuclear blood cells stimulated with tumor material. Results Neoantigen-specific T cell reactivity was detected to several neo-epitopes in the tumor-infiltrating lymphocytes of three patients while their respective cancers expressed 15, 21, and 30 non-synonymous variants. Cell sorting of tumor-infiltrating lymphocytes based on the co-expression of CD39 and CD103 pinpointed the presence of neoantigen-specific T cells in the CD39 + CD103 + T cell subset. Strikingly, the tumors containing neoantigen-reactive TIL were classified as consensus molecular subtype 4 (CMS4), which is associated with TGF-β pathway activation and worse clinical outcome. Conclusions We have detected neoantigen-targeted reactivity by autologous T cells in mismatch repair-proficient colorectal cancers of the CMS4 subtype. These findings warrant the development of specific immunotherapeutic strategies that selectively boost the activity of neoantigen-specific T cells and target the TGF-β pathway to reinforce T cell reactivity in this patient group. |
| ArticleNumber | 87 |
| Audience | Academic |
| Author | de Miranda, Noel F. C. C. Oosting, Jan Weinberg, Andrew D. Ruano, Dina van der Breggen, Ruud Ijsselsteijn, Marieke E. Farina-Sarasqueta, Arantza Duhen, Thomas Verdegaal, Els M. E. de Vries, Natasja L. van der Ploeg, Manon van den Bulk, Jitske van der Burg, Sjoerd H. Visser, Marten Peeters, Koen C. M. J. |
| Author_xml | – sequence: 1 givenname: Jitske surname: van den Bulk fullname: van den Bulk, Jitske organization: Pathology, LUMC – sequence: 2 givenname: Els M. E. surname: Verdegaal fullname: Verdegaal, Els M. E. organization: Medical Oncology, Oncode Institute, LUMC – sequence: 3 givenname: Dina surname: Ruano fullname: Ruano, Dina organization: Pathology, LUMC – sequence: 4 givenname: Marieke E. surname: Ijsselsteijn fullname: Ijsselsteijn, Marieke E. organization: Pathology, LUMC – sequence: 5 givenname: Marten surname: Visser fullname: Visser, Marten organization: Medical Oncology, Oncode Institute, LUMC – sequence: 6 givenname: Ruud surname: van der Breggen fullname: van der Breggen, Ruud organization: Pathology, LUMC – sequence: 7 givenname: Thomas surname: Duhen fullname: Duhen, Thomas organization: Earle A. Chiles Institute – sequence: 8 givenname: Manon surname: van der Ploeg fullname: van der Ploeg, Manon organization: Pathology, LUMC – sequence: 9 givenname: Natasja L. surname: de Vries fullname: de Vries, Natasja L. organization: Immunohematology and Blood Transfusion, LUMC – sequence: 10 givenname: Jan surname: Oosting fullname: Oosting, Jan organization: Pathology, LUMC – sequence: 11 givenname: Koen C. M. J. surname: Peeters fullname: Peeters, Koen C. M. J. organization: Surgery, LUMC – sequence: 12 givenname: Andrew D. surname: Weinberg fullname: Weinberg, Andrew D. organization: Earle A. Chiles Institute, AgonOx – sequence: 13 givenname: Arantza surname: Farina-Sarasqueta fullname: Farina-Sarasqueta, Arantza organization: Pathology, LUMC – sequence: 14 givenname: Sjoerd H. surname: van der Burg fullname: van der Burg, Sjoerd H. organization: Medical Oncology, Oncode Institute, LUMC – sequence: 15 givenname: Noel F. C. C. orcidid: 0000-0001-6122-1024 surname: de Miranda fullname: de Miranda, Noel F. C. C. email: N.F.de_Miranda@lumc.nl organization: Pathology, LUMC |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31888734$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kl2L1DAYhYusuB_6A7yRgCDedE2aNE1uhGXxY2HRGwXvQiZ9M5MxTcakXZl_b-rsujOLSgsNyXNOmpNzWh2FGKCqnhN8TojgbzKhuKM1JrLGXHa1eFSdkK7ltZTs29He-Lg6zXmNMWcN655Ux5QIITrKTqrvnyDqMLolhDpvwDjrDHLDMAU3bpELyMefaJhGPboY0GJKPQRkoo8JzKg9MjoYSBlFi8YVlJWQIeQpoyF6MJPXCeVpMW43gNjT6rHVPsOz2-9Z9fX9uy-XH-vrzx-uLi-ua9NhPNYLynsQRBCGqeywbXXHNaa05aKMLe1kj63UjWCUYy5Mr7U0LbaNNAsrKKZn1dXOt496rTbJDTptVdRO_Z6Iaal0Gp3xoAhuacMaIZluGMetKK-VDSWayLZhtni93XltpsUAvYEwJu0PTA9XglupZbxRXFKBMSsGr28NUvwxQR7V4LIB73WAOGXVUEo4oZS3BX35AF3HKYUSVaEYIW0nhbinlrocwAUby75mNlUXnGDCmBBzBud_ocrTw-DKLYF1Zf5A8GpPsALtx1WOfprvPR-CL_YT-RPFXacK0O0Ak2LOCawybtef8gvOl8zV3F61a68q7VVze9V8NPJAeWf-P02z0-TChiWk-9D-LfoFwxP-kA |
| CitedBy_id | crossref_primary_10_1186_s12876_025_03918_8 crossref_primary_10_3390_vaccines13090911 crossref_primary_10_1038_s41467_021_21383_1 crossref_primary_10_1002_gch2_202200186 crossref_primary_10_1158_2326_6066_CIR_20_1024 crossref_primary_10_3892_ol_2022_13208 crossref_primary_10_1158_2326_6066_CIR_20_0270 crossref_primary_10_3390_biomedicines13051217 crossref_primary_10_1016_j_csbj_2023_10_050 crossref_primary_10_1080_14622416_2025_2534319 crossref_primary_10_1172_JCI156821 crossref_primary_10_3389_fimmu_2021_724883 crossref_primary_10_1080_2162402X_2025_2546406 crossref_primary_10_1136_jcp_2023_209328 crossref_primary_10_1038_s41467_024_55420_6 crossref_primary_10_3389_fimmu_2022_912393 crossref_primary_10_3389_fimmu_2024_1414376 crossref_primary_10_1136_bmjonc_2024_000472 crossref_primary_10_1038_s41416_023_02483_9 crossref_primary_10_1038_s41598_024_80803_6 crossref_primary_10_1080_08820139_2024_2447780 crossref_primary_10_1136_jitc_2022_005887 crossref_primary_10_3389_fimmu_2023_1057292 crossref_primary_10_3389_fimmu_2022_1003626 crossref_primary_10_1016_j_jss_2021_09_007 crossref_primary_10_1136_jitc_2021_002595 crossref_primary_10_3389_froh_2022_902160 crossref_primary_10_2147_OTT_S297272 crossref_primary_10_1038_s41423_021_00634_7 crossref_primary_10_1016_j_labinv_2023_100303 crossref_primary_10_1007_s00595_023_02773_y crossref_primary_10_1080_21645515_2021_1891814 crossref_primary_10_1155_2022_8270305 crossref_primary_10_3390_cancers12113440 crossref_primary_10_3389_fimmu_2023_1053920 crossref_primary_10_1016_j_jtho_2021_01_1624 crossref_primary_10_1080_21645515_2021_2024416 crossref_primary_10_1186_s12943_022_01569_x crossref_primary_10_1038_s41568_021_00346_0 crossref_primary_10_3390_cancers12051214 crossref_primary_10_1038_s41392_022_00922_2 crossref_primary_10_1016_j_immuni_2022_03_008 crossref_primary_10_3389_fonc_2020_545385 |
| Cites_doi | 10.1056/NEJMoa1500596 10.1093/bioinformatics/btu548 10.1126/science.aad1253 10.1016/S2468-1253(16)30014-0 10.1038/s41586-018-0792-9 10.1093/annonc/mdz052 10.1038/nm.3967 10.1084/jem.163.5.1037 10.1158/0008-5472.CAN-17-0337 10.1016/j.immuni.2019.03.024 10.1126/scisignal.aav3334 10.3322/caac.21492 10.1038/s41586-018-0130-2 10.1098/rsob.180037 10.1038/s41591-018-0266-5 10.1038/nrc.2016.154 10.1002/ijc.30289 10.1093/bioinformatics/btp324 10.1016/j.immuni.2013.08.019 10.1126/science.1251102 10.1101/gr.129684.111 10.1038/nm.4051 10.1038/nature25492 10.1038/s41598-017-16747-x 10.1200/JCO.2012.47.7521 10.1084/jem.20030152 10.1016/j.celrep.2019.07.065 10.1038/nri1250 10.1038/s41467-018-03301-0 10.1056/NEJMoa1406498 10.1038/nature22991 10.1038/s41586-018-0810-y 10.1093/annonc/mdu479 10.1038/nature25501 10.1056/NEJMoa1609279 10.1016/j.ccr.2005.10.012 10.1126/science.aan6733 10.1038/nbt.2514 10.1110/ps.0239403 10.1126/science.aaf1490 10.1038/s41591-018-0057-z 10.1016/j.humimm.2007.03.012 10.1084/jem.166.4.991 10.1038/nature18945 10.1038/s41467-018-05072-0 10.1093/bioinformatics/btu638 10.1038/nbt.1754 10.1038/s41588-018-0312-8 10.1007/s00262-006-0214-y 10.1093/bioinformatics/btp616 10.1016/j.trecan.2016.11.008 10.1093/bioinformatics/bti310 10.4049/jimmunol.1700893 10.1093/bioinformatics/bts271 10.1002/cjp2.113 10.1146/annurev.immunol.22.012703.104538 10.1101/gr.107524.110 10.1093/nar/gkv007 10.1126/scitranslmed.aao5931 10.1093/bib/bbs017 10.1093/bioinformatics/btv639 10.1038/ng.3225 10.1038/s41416-019-0421-x 10.1126/science.aaa1348 10.1126/science.aad0095 10.1172/JCI127967 10.1186/s13059-016-0974-4 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2019 COPYRIGHT 2019 BioMed Central Ltd. 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2019 – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13073-019-0697-8 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea ProQuest Health & Medical Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database Proquest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest - Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1756-994X |
| EndPage | 15 |
| ExternalDocumentID | oai_doaj_org_article_1053242894a246058058f9231a19524f PMC6938004 A610144880 31888734 10_1186_s13073_019_0697_8 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United States Netherlands United States--US |
| GeographicLocations_xml | – name: Netherlands – name: United States – name: United States--US |
| GrantInformation_xml | – fundername: Fight Colorectal Cancer-Michael’s Mission-AACR Fellowship in Young Onset, Late-Stage Colorectal Cancer Research 2015 grantid: 15-40-1645-DEMI – fundername: ZonMw Veni grant grantid: 016.176.l44 – fundername: KWF Bas Mulder Award UL grantid: 2015-7664 – fundername: LUMC PhD fellowship grantid: - – fundername: ; grantid: 15-40-1645-DEMI – fundername: ; grantid: 2015-7664 – fundername: ; grantid: - – fundername: ; grantid: 016.176.l44 |
| GroupedDBID | --- 0R~ 2WC 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFS ACJQM ACUHS ADUKV AENEX AFKRA AFPKN AHBYD AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIAM BBNVY BENPR BHPHI BMC BPHCQ BVXVI C6C CCPQU DIK E3Z EBD EBLON EBS EJD ESX FYUFA GROUPED_DOAJ GX1 H13 HCIFZ HMCUK HYE IAO IHR IHW INH INR ITC KQ8 LK8 M1P M7P MK0 M~E O5R O5S OK1 PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO RBZ ROL RPM RSV SBL SOJ TUS UKHRP AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c700t-b36de8181403970f5a76a033568f5af379d0f9a28436068cdaa9c50f29cbf8303 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 54 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000511657500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1756-994X |
| IngestDate | Fri Oct 03 12:51:38 EDT 2025 Tue Nov 04 02:00:42 EST 2025 Thu Oct 02 10:45:12 EDT 2025 Tue Oct 14 14:11:58 EDT 2025 Tue Nov 11 10:38:54 EST 2025 Tue Nov 04 17:53:48 EST 2025 Thu May 22 21:22:17 EDT 2025 Thu Apr 03 06:59:45 EDT 2025 Sat Nov 29 06:05:11 EST 2025 Tue Nov 18 22:05:14 EST 2025 Sat Sep 06 07:28:08 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Adoptive T cell transfer (ACT) Tumor-infiltrating lymphocytes Mismatch repair-proficient (MMR-p) CMS Transforming growth factor-beta Cancer immunotherapy Neoantigen Low mutation burden |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c700t-b36de8181403970f5a76a033568f5af379d0f9a28436068cdaa9c50f29cbf8303 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-6122-1024 |
| OpenAccessLink | https://doaj.org/article/1053242894a246058058f9231a19524f |
| PMID | 31888734 |
| PQID | 2341157988 |
| PQPubID | 2040231 |
| PageCount | 15 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_1053242894a246058058f9231a19524f pubmedcentral_primary_oai_pubmedcentral_nih_gov_6938004 proquest_miscellaneous_2331613365 proquest_journals_2341157988 gale_infotracmisc_A610144880 gale_infotracacademiconefile_A610144880 gale_healthsolutions_A610144880 pubmed_primary_31888734 crossref_citationtrail_10_1186_s13073_019_0697_8 crossref_primary_10_1186_s13073_019_0697_8 springer_journals_10_1186_s13073_019_0697_8 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-12-30 |
| PublicationDateYYYYMMDD | 2019-12-30 |
| PublicationDate_xml | – month: 12 year: 2019 text: 2019-12-30 day: 30 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Genome medicine |
| PublicationTitleAbbrev | Genome Med |
| PublicationTitleAlternate | Genome Med |
| PublicationYear | 2019 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | S Colak (697_CR59) 2017; 3 E Fontana (697_CR63) 2019; 30 E Domingo (697_CR5) 2016; 1 LP Garo (697_CR49) 2019; 28 W Chen (697_CR51) 2003; 198 S Mariathasan (697_CR58) 2018; 554 697_CR69 L Li (697_CR50) 2016; 139 N Zhang (697_CR52) 2013; 39 697_CR20 E Tran (697_CR62) 2016; 375 T Duhen (697_CR40) 2018; 9 DC Koboldt (697_CR23) 2012; 22 JT Robinson (697_CR28) 2017; 77 JT Robinson (697_CR26) 2011; 29 A Szolek (697_CR21) 2014; 30 TD Wu (697_CR30) 2005; 21 F Favero (697_CR31) 2014; 26 DS Thommen (697_CR44) 2018; 24 W McLaren (697_CR29) 2016; 17 Sarah Dimeloe (697_CR56) 2019; 12 ES Trombetta (697_CR14) 2004; 23 Janos L. Tanyi (697_CR65) 2018; 10 EM Van Allen (697_CR8) 2015; 350 JH Kehrl (697_CR53) 1986; 163 RM Samstein (697_CR9) 2019; 51 E Tran (697_CR68) 2014; 344 A Gros (697_CR39) 2016; 22 EM Verdegaal (697_CR18) 2016; 536 E Tran (697_CR61) 2015; 350 S Bobisse (697_CR64) 2018; 9 DB Keskin (697_CR66) 2019; 565 K Kondo (697_CR48) 2007; 68 E Batlle (697_CR60) 2019; 50 DT Le (697_CR2) 2015; 372 GE Ranges (697_CR54) 1987; 166 K Cibulskis (697_CR22) 2013; 31 DT Le (697_CR4) 2017; 357 M Nielsen (697_CR33) 2003; 12 EME Verdegaal (697_CR46) 2007; 56 H Thorvaldsdóttir (697_CR27) 2013; 14 697_CR45 N Hilf (697_CR67) 2019; 565 NA Rizvi (697_CR11) 2015; 348 H Li (697_CR19) 2009; 25 S Anders (697_CR36) 2014; 31 ME Ritchie (697_CR38) 2015; 43 A Calon (697_CR13) 2015; 47 N McGranahan (697_CR10) 2016; 351 Y Simoni (697_CR47) 2018; 557 Alena Gros (697_CR43) 2019; 129 A McKenna (697_CR25) 2010; 20 DVF Tauriello (697_CR57) 2018; 554 PA Ott (697_CR16) 2017; 547 M Yarchoan (697_CR3) 2017; 17 V Jurtz (697_CR34) 2017; 199 W Scheper (697_CR17) 2019; 25 JW Yewdell (697_CR15) 2003; 3 M Andreatta (697_CR32) 2016; 32 F Bray (697_CR1) 2018; 68 A Snyder (697_CR6) 2014; 371 N van Rooij (697_CR7) 2013; 31 PW Eide (697_CR35) 2017; 7 J Guinney (697_CR12) 2015; 21 Marieke Erica Ijsselsteijn (697_CR41) 2019; 120 ME Ijsselsteijn (697_CR42) 2018; 5 DA Thomas (697_CR55) 2005; 8 MD Robinson (697_CR37) 2009; 26 CT Saunders (697_CR24) 2012; 28 |
| References_xml | – volume: 372 start-page: 2509 issue: 26 year: 2015 ident: 697_CR2 publication-title: N Engl J Med doi: 10.1056/NEJMoa1500596 – volume: 30 start-page: 3310 issue: 23 year: 2014 ident: 697_CR21 publication-title: Bioinformatics (Oxford, England) doi: 10.1093/bioinformatics/btu548 – volume: 350 start-page: 1387 year: 2015 ident: 697_CR61 publication-title: Science (New York, NY) doi: 10.1126/science.aad1253 – volume: 1 start-page: 207 issue: 3 year: 2016 ident: 697_CR5 publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(16)30014-0 – volume: 565 start-page: 234 issue: 7738 year: 2019 ident: 697_CR66 publication-title: Nature. doi: 10.1038/s41586-018-0792-9 – volume: 30 start-page: 520 issue: 4 year: 2019 ident: 697_CR63 publication-title: Ann Oncol doi: 10.1093/annonc/mdz052 – volume: 21 start-page: 1350 issue: 11 year: 2015 ident: 697_CR12 publication-title: Nat Med doi: 10.1038/nm.3967 – volume: 163 start-page: 1037 issue: 5 year: 1986 ident: 697_CR53 publication-title: J Exp Med doi: 10.1084/jem.163.5.1037 – volume: 77 start-page: e31 issue: 21 year: 2017 ident: 697_CR28 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-17-0337 – volume: 50 start-page: 924 issue: 4 year: 2019 ident: 697_CR60 publication-title: Immunity. doi: 10.1016/j.immuni.2019.03.024 – volume: 12 start-page: eaav3334 issue: 599 year: 2019 ident: 697_CR56 publication-title: Science Signaling doi: 10.1126/scisignal.aav3334 – volume: 68 start-page: 394 issue: 6 year: 2018 ident: 697_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21492 – volume: 557 start-page: 575 issue: 7706 year: 2018 ident: 697_CR47 publication-title: Nature. doi: 10.1038/s41586-018-0130-2 – ident: 697_CR20 – ident: 697_CR69 doi: 10.1098/rsob.180037 – volume: 25 start-page: 89 issue: 1 year: 2019 ident: 697_CR17 publication-title: Nat Med doi: 10.1038/s41591-018-0266-5 – volume: 17 start-page: 209 issue: 4 year: 2017 ident: 697_CR3 publication-title: Nat Rev Cancer doi: 10.1038/nrc.2016.154 – volume: 139 start-page: 2261 issue: 10 year: 2016 ident: 697_CR50 publication-title: Int J Cancer doi: 10.1002/ijc.30289 – volume: 25 start-page: 1754 issue: 14 year: 2009 ident: 697_CR19 publication-title: Bioinformatics. doi: 10.1093/bioinformatics/btp324 – volume: 39 start-page: 687 issue: 4 year: 2013 ident: 697_CR52 publication-title: Immunity. doi: 10.1016/j.immuni.2013.08.019 – volume: 344 start-page: 641 issue: 6184 year: 2014 ident: 697_CR68 publication-title: Science (New York, NY) doi: 10.1126/science.1251102 – volume: 22 start-page: 568 issue: 3 year: 2012 ident: 697_CR23 publication-title: Genome Res doi: 10.1101/gr.129684.111 – volume: 22 start-page: 433 issue: 4 year: 2016 ident: 697_CR39 publication-title: Nat Med doi: 10.1038/nm.4051 – volume: 554 start-page: 538 issue: 7693 year: 2018 ident: 697_CR57 publication-title: Nature. doi: 10.1038/nature25492 – volume: 7 start-page: 16618 issue: 1 year: 2017 ident: 697_CR35 publication-title: Sci Rep doi: 10.1038/s41598-017-16747-x – volume: 31 start-page: e439 issue: 32 year: 2013 ident: 697_CR7 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.47.7521 – volume: 198 start-page: 1875 issue: 12 year: 2003 ident: 697_CR51 publication-title: J Exp Med doi: 10.1084/jem.20030152 – volume: 28 start-page: 3353 issue: 13 year: 2019 ident: 697_CR49 publication-title: Cell Reports doi: 10.1016/j.celrep.2019.07.065 – volume: 3 start-page: 952 issue: 12 year: 2003 ident: 697_CR15 publication-title: Nat Rev Immunol doi: 10.1038/nri1250 – volume: 9 start-page: 1092 issue: 1 year: 2018 ident: 697_CR64 publication-title: Nat Commun doi: 10.1038/s41467-018-03301-0 – volume: 371 start-page: 2189 issue: 23 year: 2014 ident: 697_CR6 publication-title: N Engl J Med doi: 10.1056/NEJMoa1406498 – volume: 547 start-page: 217 issue: 7662 year: 2017 ident: 697_CR16 publication-title: Nature. doi: 10.1038/nature22991 – volume: 565 start-page: 240 issue: 7738 year: 2019 ident: 697_CR67 publication-title: Nature. doi: 10.1038/s41586-018-0810-y – volume: 26 start-page: 64 issue: 1 year: 2014 ident: 697_CR31 publication-title: Ann Oncol doi: 10.1093/annonc/mdu479 – volume: 554 start-page: 544 year: 2018 ident: 697_CR58 publication-title: Nature. doi: 10.1038/nature25501 – volume: 375 start-page: 2255 issue: 23 year: 2016 ident: 697_CR62 publication-title: N Engl J Med doi: 10.1056/NEJMoa1609279 – volume: 8 start-page: 369 issue: 5 year: 2005 ident: 697_CR55 publication-title: Cancer Cell doi: 10.1016/j.ccr.2005.10.012 – volume: 357 start-page: 409 issue: 6349 year: 2017 ident: 697_CR4 publication-title: Science (New York, NY) doi: 10.1126/science.aan6733 – volume: 31 start-page: 213 issue: 3 year: 2013 ident: 697_CR22 publication-title: Nat Biotechnol doi: 10.1038/nbt.2514 – volume: 12 start-page: 1007 issue: 5 year: 2003 ident: 697_CR33 publication-title: Protein Sci doi: 10.1110/ps.0239403 – volume: 351 start-page: 1463 issue: 6280 year: 2016 ident: 697_CR10 publication-title: Science (New York, NY) doi: 10.1126/science.aaf1490 – volume: 24 start-page: 994 issue: 7 year: 2018 ident: 697_CR44 publication-title: Nat Med doi: 10.1038/s41591-018-0057-z – volume: 68 start-page: 563 issue: 7 year: 2007 ident: 697_CR48 publication-title: Hum Immunol doi: 10.1016/j.humimm.2007.03.012 – volume: 166 start-page: 991 issue: 4 year: 1987 ident: 697_CR54 publication-title: J Exp Med doi: 10.1084/jem.166.4.991 – volume: 536 start-page: 91 issue: 7614 year: 2016 ident: 697_CR18 publication-title: Nature. doi: 10.1038/nature18945 – volume: 9 start-page: 2724 issue: 1 year: 2018 ident: 697_CR40 publication-title: Nat Commun doi: 10.1038/s41467-018-05072-0 – ident: 697_CR45 – volume: 31 start-page: 166 issue: 2 year: 2014 ident: 697_CR36 publication-title: Bioinformatics (Oxford, England) doi: 10.1093/bioinformatics/btu638 – volume: 29 start-page: 24 year: 2011 ident: 697_CR26 publication-title: Nat Biotechnol doi: 10.1038/nbt.1754 – volume: 51 start-page: 202 issue: 2 year: 2019 ident: 697_CR9 publication-title: Nat Genet doi: 10.1038/s41588-018-0312-8 – volume: 56 start-page: 587 issue: 5 year: 2007 ident: 697_CR46 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-006-0214-y – volume: 26 start-page: 139 issue: 1 year: 2009 ident: 697_CR37 publication-title: Bioinformatics (Oxford, England) doi: 10.1093/bioinformatics/btp616 – volume: 3 start-page: 56 issue: 1 year: 2017 ident: 697_CR59 publication-title: Trends Cancer doi: 10.1016/j.trecan.2016.11.008 – volume: 21 start-page: 1859 issue: 9 year: 2005 ident: 697_CR30 publication-title: Bioinformatics. doi: 10.1093/bioinformatics/bti310 – volume: 199 start-page: 3360 issue: 9 year: 2017 ident: 697_CR34 publication-title: J Immunol (Baltimore, Md : 1950) doi: 10.4049/jimmunol.1700893 – volume: 28 start-page: 1811 issue: 14 year: 2012 ident: 697_CR24 publication-title: Bioinformatics. doi: 10.1093/bioinformatics/bts271 – volume: 5 start-page: 3 issue: 1 year: 2018 ident: 697_CR42 publication-title: J Pathol Clin Res doi: 10.1002/cjp2.113 – volume: 23 start-page: 975 issue: 1 year: 2004 ident: 697_CR14 publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.22.012703.104538 – volume: 20 start-page: 1297 issue: 9 year: 2010 ident: 697_CR25 publication-title: Genome Res doi: 10.1101/gr.107524.110 – volume: 43 start-page: e47 issue: 7 year: 2015 ident: 697_CR38 publication-title: Nucleic Acids Research doi: 10.1093/nar/gkv007 – volume: 10 start-page: eaao5931 issue: 436 year: 2018 ident: 697_CR65 publication-title: Science Translational Medicine doi: 10.1126/scitranslmed.aao5931 – volume: 14 start-page: 178 issue: 2 year: 2013 ident: 697_CR27 publication-title: Brief Bioinform doi: 10.1093/bib/bbs017 – volume: 32 start-page: 511 issue: 4 year: 2016 ident: 697_CR32 publication-title: Bioinformatics (Oxford, England) doi: 10.1093/bioinformatics/btv639 – volume: 47 start-page: 320 issue: 4 year: 2015 ident: 697_CR13 publication-title: Nat Genet doi: 10.1038/ng.3225 – volume: 120 start-page: 815 issue: 8 year: 2019 ident: 697_CR41 publication-title: British Journal of Cancer doi: 10.1038/s41416-019-0421-x – volume: 348 start-page: 124 issue: 6230 year: 2015 ident: 697_CR11 publication-title: Science (New York, NY) doi: 10.1126/science.aaa1348 – volume: 350 start-page: 207 issue: 6257 year: 2015 ident: 697_CR8 publication-title: Science (New York, NY) doi: 10.1126/science.aad0095 – volume: 129 start-page: 4992 issue: 11 year: 2019 ident: 697_CR43 publication-title: Journal of Clinical Investigation doi: 10.1172/JCI127967 – volume: 17 start-page: 122 issue: 1 year: 2016 ident: 697_CR29 publication-title: Genome Biol doi: 10.1186/s13059-016-0974-4 |
| SSID | ssj0064247 |
| Score | 2.4410548 |
| Snippet | Background
The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch... The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch... Background The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch... Abstract Background The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 87 |
| SubjectTerms | Adoptive T cell transfer (ACT) Antigenic determinants Antigens Antigens, Neoplasm - chemistry Antigens, Neoplasm - immunology Bioinformatics Biomedical and Life Sciences Biomedicine Blood cells Bone morphogenetic proteins Cancer Cancer immunotherapy Cancer patients Cancer Research Cancer treatment CD103 antigen CD8-Positive T-Lymphocytes - cytology CD8-Positive T-Lymphocytes - metabolism Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - immunology Colorectal Neoplasms - pathology Colorectal Neoplasms - therapy Deoxyribonucleic acid DNA DNA Mismatch Repair DNA-Binding Proteins - genetics Epitopes Epitopes - chemistry Epitopes - immunology Epitopes - pharmacology Gene expression Genetic aspects Genomes Health aspects Human Genetics Humans Immune checkpoint Immunotherapy Interferon-gamma - metabolism Low mutation burden Lymphocytes Lymphocytes T Lymphocytes, Tumor-Infiltrating - cytology Lymphocytes, Tumor-Infiltrating - drug effects Lymphocytes, Tumor-Infiltrating - metabolism Medical prognosis Medicine/Public Health Metabolomics Microfilament Proteins - genetics Mismatch repair Mismatch repair-proficient (MMR-p) Mutation Neoantigens Patients Peptides Peptides - chemical synthesis Peptides - pharmacology Pharmacy Scientific equipment industry Systems Biology T cells T-Lymphocyte Subsets - cytology T-Lymphocyte Subsets - metabolism Transcription Factors - genetics Transforming Growth Factor beta - metabolism Transforming growth factor-beta Transforming growth factors Tumor antigens Tumor immune microenvironment and immunotherapy Tumor-infiltrating lymphocytes Tumors |
| SummonAdditionalLinks | – databaseName: Biological Science Database dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BAYkLb2iggJGQkEBRkzhO7BMqiIoDWvUAqDfL69iwok3azQbUf8-M8ygpohekPazW41Vij78Z2zPfALysEuNUVqjYWyPjPC9VbJTnsXXKG4U2Q4TYnK-fysVCHh6qg-HArR3CKkdMDEBdNZbOyHczhNtUELvW25PTmKpG0e3qUELjKlwjlgQeQvcORiRG1zovh5vMVBa7bUoKjZtnyrtXCM4zWxQo-_8G5j8s08WoyQtXp8Ei7d_-33e5A7cGX5Tt9cpzF664-h7c6KtTnt2HHwvX4LgTXWdMCZkUVMRWIZ9kc8ZWNTtqfrHjrr_LZ8uQD8GIBJtAFP_XkkKtW9Z4hl4mttAxdtu17HgsycvabklnwCx_AF_2P3x-_zEeajPEtkySTbzkReXQ2BPdnyoTL0xZmIRzUUj87nmpqsQrg8aP4xZJ2soYZUXiM2WXXqLdfAhbdVO7bWDSOcErroSlvVmpDHoM6GVmlUurJToUESTjLGk7EJdT_YwjHTYwstD9xGqcWE0Tq2UEr6cuJz1rx2XC72jqJ0Ei3A4_NOtveli_2FuQ6ylVbrJwlYwfT86xSZXIch_Bc1Ic3WevTrCh9woqhkwoGcGrIEHAgY9vzZD_gINAFFwzyZ2ZJC54O28etUoPgNPqc5WK4MXUTD0piK52TUcyHP17zgsRwaNel6eXRmhHc8PzCMqZls9GZd5Sr74HOvJCcdx1YM8343o4f6x_Dvrjy1_iCdzMaJ0So2ayA1ubdeeewnX7c7Nq18_CKv8N3wJXbQ priority: 102 providerName: ProQuest – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ri9QwEB_0VPDL-TytnhpBEJRy3aZpk4-nePhBFvFx3LeQpoku3rWy3Xrcf-9M-tCeD1DYD8tmZmmn82wyvwF4UiXGqTRXsbdGxllWqNgoz2PrlDcKY4YIZ3MO3xTLpTw6Um-HPu52PO0-bkkGTx3MWuZ77YLUEUtf6ppX6FovwiWMdpKs8d37w9H9Yj6dFcP25W_ZZgEo4PT_6o1_Ckfnj0qe2y8NYejg2n_dwHXYHrJOtt-ryQ244OqbcKWfQ3l2C74sXYMSJmDOmFov6fgQW4XOkc0ZW9XsuDllJ12_a8_K0PnACO6a3CX-ryXVWbes8QzzSVyhF9Zt17KTcfgua7uS3vay7DZ8PHj14eXreJjCENsiSTZxyfPKYVgnYD9VJF6YIjcJ5yKX-N3zQlWJVwbDHMdiSNrKGGVF4lNlSy8xQu7AVt3U7i4w6ZzgFVfCUhVWKIO5AeaTaeUWVYmpQwTJ-Gi0HSDKaVLGsQ6lisx1L0ONMtQkQy0jeDaxfO3xOf5G_IKe90RI0Nrhh2b9SQ-WityCkkypMpOGTWP8eEqDzUKJNPMRPCJt0X2f6uQg9H5OY4_JH0bwNFCQi8DLt2bodEAhENjWjHJ3RommbefLo0bqwbW0OsW8YyEIZi6Cx9MycdJxudo1HdFwzOQ5z0UEd3oFnm4anTgGFp5FUMxUeyaV-Uq9-hyAx3PFsb5Azuejgv-4rD8K_d4_Ud-HqylZCEFpJruwtVl37gFctt82q3b9MFj6dyDkTPk priority: 102 providerName: Springer Nature |
| Title | Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4 |
| URI | https://link.springer.com/article/10.1186/s13073-019-0697-8 https://www.ncbi.nlm.nih.gov/pubmed/31888734 https://www.proquest.com/docview/2341157988 https://www.proquest.com/docview/2331613365 https://pubmed.ncbi.nlm.nih.gov/PMC6938004 https://doaj.org/article/1053242894a246058058f9231a19524f |
| Volume | 11 |
| WOSCitedRecordID | wos000511657500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: RBZ dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: DOA dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: M~E dateStart: 20090101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database (ProQuest) customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: M7P dateStart: 20150101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: 7X7 dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest - Publicly Available Content Database customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: PIMPY dateStart: 20150101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: BENPR dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: RSV dateStart: 20090101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEB_0VPBF_LZ6rhEEQSl2m7ZJHu_kDgVdllOP9Slk0wQX71rZbpX7751J2_V6or4Iy7LbJEt3Mp_NzG8AnpWJcSotVOytkXGWCRUb5XlsnfJGoc3IQ27O8Tsxm8nFQs3PtfqinLAOHrgjHEp1TjZfqsyk4QwPX568EjNVeZp50r7o9QzBVKeD0anORH-GOZXFq2ZKrIxhM1XcK1TLIysUwPp_V8nnbNLFfMkLh6bBFh3ehBu9E8n2upu_BZdcdRuudW0lz-7A15mrkWCEsxlTJSVlA7FVKATZnLFVxU7qH-y07Q7h2TIUMjBCrybth79riRPWDas9Q_cQR-j5c9M27HTopcuadkkPb1l2Fz4dHnx8_SbumyrEViTJJl7yonRopQmnT4nE50YUJuE8LyR-9lyoMvHKoNXiGNtIWxqjbJ74VNmll2jw7sFOVVfuATDpXM5LrnJLQZVQBk09uodp6ablEj2BCJKByNr2iOPU-OJEh8hDFrrbF437omlftIzgxXbJtw5u42-T92nnthMJKTtcQP7RPf_of_FPBE9o33VXdrqVd71XUBdjUm8RPA8zSOLx9q3pCxeQCISdNZq5O5qJkmrHwwNv6V5TNDpFN2KaE2pcBE-3w7SSst8qV7c0h6NjznmRR3C_Y8Xtn0adjHaCZxGIEZOOqDIeqVZfAo54oTiGC7jy5cDOv27rj0R_-D-I_giupySMBJiZ7MLOZt26x3DVft-smvUELouFCO9yAlf2D2bzo0kQ7wll5s7x2vzt-_ln_Hb04fgn3UdNfg |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VFAQX3g9DoYsEQgJZdbx-7QGh8qgaNY16KKicls16FyJau8QJVf4Uv5GZtZ3iInrrASmHKDtreTcz38zszgPgWR4oI8JE-FarzI-iVPhKWO5rI6wSqDNiF5vzaZiORtnBgdhbgV9tLgyFVbaY6IA6LzWdkW-ECLf9mKprvTn-4VPXKLpdbVto1GyxYxYn6LJVrwfv8f99HoZbH_bfbftNVwFfp0Ew88c8yQ2qKSpUJ9LAxipNVMB5nGT43fJU5IEVCmGbo3Gf6VwpoePAhkKPbYaIj8-9BKsRMnvWg9W9we7e5xb70ZiP0ubutJ8lG1WfRAjddcr0F6gOOtrPNQn4WxX8oQvPxmmeuax1OnDrxv-2ezfhemNts81aPG7Biiluw5W6_-biDnwfmRI5iwqS-pRySmFTbOIyZmYLNinYYXnCjuZ1tAIbu4wPRmW-SU3gczWJzLRipWVoR-MIHdRX84odtU2HWTUf0yk3i-7CxwtZ6T3oFWVhHgDLjIl5zkWsyftMhUKbCO3oMDf9fIwmkwdByxVSN6XZqUPIoXQuWpbImpEkMpIkRpKZBy-XU47ruiTnEb8lVlsSUklx90M5_SobhMLZMRnXmYhU6C7L8WPJ_Fd9EYeR9WCdGFXW-blLYJSbCbV7Jj3gwQtHQdCIr69Vk-GBm0BFxjqUax1KhDTdHW65WDaQWslTFvbg6XKYZlKYYGHKOdFw9GA4T2IP7teys1w0Ki9UqDzyIO1IVWdXuiPF5JsruJ4Ijn4VznzVyt_pa_1z0x-ev4h1uLq9vzuUw8Fo5xFcCwkjqH5osAa92XRuHsNl_XM2qaZPGoxh8OWiBfM3qyuz6g |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3ra9RAEB-0avGL72q02hUEQQnNZbNJ9mN9HIrlKKil35bNZlcP26RcEqX_vTOb5DT1ASLch-N29kgms_PIzPwG4EkZaSvjVIbO6DxMkkyGWjoeGiudlmgzhK_NOdzPFov86EgeDHNOm7HafUxJ9j0NhNJUtbunpeuPeJ7uNjMSTQyDqYNeopq9CJcSmhlE4fr7w1EVo2-dZEMq87fbJsbIY_b_qpl_Mk3nyybP5U69SZpf_--buQHXBm-U7fXicxMu2OoWXOnnU57dhi8LWyPnCbAzpJZMKitiS99R0p6xZcWO62_spOuz-azwHRGMYLBJjeL_GhKpVcNqx9DPxBV6kd10DTsZh_KypivoLTBL7sDH-esPL9-Ew3SG0GRR1IYFT0uL5p4A_2QWOaGzVEecizTH745nsoyc1Gj-OAZJuSm1lkZELpamcDlazi3YqOrK3gOWWyt4yaUwFJ1lUqPPgH5mXNpZWaBLEUA0PiZlBuhymqBxrHwIk6eq56FCHiriocoDeLbectrjdvyN-AU9-zUhQW77H-rVJzWcYNwtyPnMZaJjn0zGjyP3WM-kiBMXwA5Jjur7V9eKQ-2lNA6Z9GQATz0FqQ68fKOHDghkAoFwTSi3J5R45M10eZRONaicRsXoj8wEwc8F8Hi9TDupjK6ydUc0HD18zlMRwN1emNc3jcodDQ5PAsgmYj7hynSlWn72gOSp5Bh34M7no7D_uKw_Mv3-P1HvwObBq7naf7t49wCuxnRYCG0z2oaNdtXZh3DZfG2XzeqRVwDfAcg4WME |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neoantigen-specific+immunity+in+low+mutation+burden+colorectal+cancers+of+the+consensus+molecular+subtype+4&rft.jtitle=Genome+medicine&rft.au=Jitske+van+den+Bulk&rft.au=Els+M.+E.+Verdegaal&rft.au=Dina+Ruano&rft.au=Marieke+E.+Ijsselsteijn&rft.date=2019-12-30&rft.pub=BMC&rft.eissn=1756-994X&rft.volume=11&rft.issue=1&rft.spage=1&rft.epage=15&rft_id=info:doi/10.1186%2Fs13073-019-0697-8&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_1053242894a246058058f9231a19524f |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-994X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-994X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-994X&client=summon |